You can accelerate drug development in ITP

Important research records are trapped in hospitals across the country. As a result, drug researchers can’t access the information they need to advance treatments.

But as a patient, you can. Unlock your records and contribute them to research, privately and securely.

Questions? Check out our FAQ
By joining the ITP program, you will help advance new research. If you know other patients or families who may be interested, you can help by sharing this link.
Neo.life
Neo.life
Mens Health Magazine
Mens Health Magazine
Village Global
Village Global
Xconomy
Xconomy
Techcrunch
Techcrunch
CNBC
CNBC
LUX
LUX

Who’s involved?

Jenny Despotovic (Baylor College of Medicine)
Jenny Despotovic (Baylor College of Medicine)
Rachael Grace (Boston Children’s Hospital)
Rachael Grace (Boston Children’s Hospital)
Michele Lambert (Children’s Hospital of Philadelphia)
Michele Lambert (Children’s Hospital of Philadelphia)
RDMD Research for ITP is approved and monitored by an independent ethics review board called WIRB (Western Institutional Review Board). WIRB is a group of people who review research studies to protect the rights and welfare of human subjects. They provide in-depth regulatory expertise to support development of research protocols and documentation.Read more.

Why join the ITP program?

Key benefits for you:

Reduce the time for idiopathic thrombocytopenic purpura drug development

All your medical data in one place

Follow new clinical trials

Make your de-identified health information part of multiple research projects


Your dashboard
Your dashboard

For the future

For the future

Help researchers get the information they need to advance development of new drug and gene therapies.

For the ITP community

For the ITP community

Jumpstart research and increase knowledge and understanding of idiopathic thrombocytopenic purpura.

For you

For you

See all your records in one place. Track how you are contributing to research and be notified about new clinical trials.

How it works

Sign up

1. Sign up

Create your private account and review our research consent (takes about 10 minutes)

We get to work

2. We get to work

We do all the behind-the-scenes work to retrieve and process your records

Empower research

3. Empower research

Track your contribution to research projects and, based on your records, find out if you qualify for new clinical trials based on your records

Be part of research

Questions? Check out our FAQ

Clinical trials for ITP

Stay in the loop. We’re monitoring idiopathic thrombocytopenic purpura clinical trials that may be interesting for patients. We can contact you if we find potentially matching trials, and keep you up to date if there are new trials or changes.

Join the ITP program

Tracking 3 trials

AmgenActive, not recruiting

Single Arm, Open-label, Long-term Study of Romiplostim in Thrombocytopenic Pediatric Subjects With ITP.

OctapharmaWaiting to recruit

Study to Evaluate the Efficacy and Safety of PANZYGA in Pediatric Patients With Chronic Immune Thrombocytopenia (ITP)

Boston Children’s HospitalRecruiting

Association of Platelet Parameters With Bleeding Severity in Children With ITP

See clinicaltrials.gov for more information

Our values & principles.

1
Patients own their data

We believe that the only way to keep data accessible to the researchers who need it is by enabling patients to own and control their own data. Patients decide for themselves whether they want to privately and securely contribute to research, rather than having the decision made on their behalf.

2
We protect patient privacy

We abide by a strict research consent and privacy policy. We only share de-identified data with researchers, foundations, and therapeutic companies with patients’ consent. Protecting the privacy of patients and ensuring the security of their information is our highest priority.

3
Researchers gain access

We aim to make useful data accessible to all researchers who have legitimate research questions or research programs. For academic research, we offer access without charge. We take research ethics seriously, and we have policies in place to ensure that research is conducted with integrity.

4
Inclusiveness in the community

We don’t like to take sides—we give all members of the community the option to get involved. Success in rare disease research takes a village and we always welcome additional collaborators who can advance and benefit from the mission.

5
Driving forward therapeutic development

Our primary mission is to accelerate drug development, so we prioritize generating insights specifically relevant to therapeutic research. We invest deeply in quality, security, and compliance to make this a reality.

How we got started

“Patients shouldn’t be bystanders in drug development.”

– Onno Faber (Founder of RDMD)

Four years ago, I started experiencing hearing loss in my left ear. Doctors prescribed me steroids, thinking it was an infection, but the deterioration did not slow down. After numerous failed treatments, a specialist finally ordered an MRI, whereupon he discovered a large tumor on my left hearing nerve. Months later, another tumor was discovered in my right hearing nerve, and another on my spine. I was diagnosed with a rare genetic disease called NF2 (Neurofibromatosis Type 2), a disease that affects only 1 in 30,000 people. It completely changed my perspective.

All my life, I’ve been a technology entrepreneur, beginning with a tech company I started in high school. I’m now applying everything I’ve learned throughout my career to build RDMD, where we’re helping to accelerate treatments for patients with rare disease. Our mission is ambitious, but I can’t imagine working on anything more important than this.

– Onno

Onno FaberPhoto Credit: from Neo.life by Damien Maloney

Our work with ITP research

Primary immune thrombocytopenia (also known as idiopathic thrombocytopenic purpura, or ITP), is an autoimmune bleeding disorder. It is caused by low levels of platelets, which are involved in clotting and are important for preventing and stopping bleeding. Some patients have symptoms such as bleeding under the skin, recurrent nosebleeds, and, rarely, dangerous bleeding in the GI system or in the brain. Many patients also experience fatigue. ITP can affect children and adults, and there are several treatment options available. Children often improve over time, with or without treatment. In adults, patients often respond to initial therapy but maybe experience relapses. There is a subset of ITP patients who do not respond well to treatment and remain at high risk for dangerous, life-threatening bleeding events.

RDMD drives research on your condition as well as research on general health and wellness.

  • Jumpstart
  • Accelerate
  • Insights

The ITP program is in the jumpstart stage.

Be part of research